Suppr超能文献

唐氏综合征呼吸道感染管理的证据有限:一项系统评价。

Limited Evidence on the Management of Respiratory Tract Infections in Down's Syndrome: A Systematic Review.

作者信息

Manikam Logan, Reed Kate, Venekamp Roderick P, Hayward Andrew, Littlejohns Peter, Schilder Anne, Lakhanpaul Monica

机构信息

From the *Institute of Child Health, University College London; †Guy's King's & St Thomas' School of Medical Education, King's College London, London, United Kingdom; ‡Julius Center for Health Sciences and Primary Care and Department of Otorhinolaryngology, University Medical Center Utrecht, Utrecht, the Netherlands; §UCL Farr Institute of Health Informatics, University College London; ¶Division of Health and Social Care Research, King's College London; and ‖evidENT, Ear Institute, University College London, London, United Kingdom.

出版信息

Pediatr Infect Dis J. 2016 Oct;35(10):1075-9. doi: 10.1097/INF.0000000000001243.

Abstract

AIMS

To systematically review the effectiveness of preventative and therapeutic interventions for respiratory tract infections (RTIs) in people with Down's syndrome.

METHODS

Databases were searched for any published and ongoing studies of respiratory tract diseases in children and adults with Down's syndrome. These databases were searched for controlled trials, cohort studies and controlled before-after studies. Trial registries were searched for ongoing studies. Initially, all study types were included to provide a broad overview of the existing evidence base. However, those with a critical risk of bias were excluded using the Cochrane Risk of Bias tool.

RESULTS

A total of 13,575 records were identified from which 5 studies fulfilled the eligibility criteria and 3 fulfilled our criteria for data extraction. One randomized controlled trial of moderate risk of bias compared zinc therapy with placebo. Outcome data were only reported for 50 (78%) children who presented with extreme symptoms; no benefit of zinc therapy was found. One non-randomized controlled trial with serious risk of bias included 26 children and compared pidotimod (an immunostimulant) with no treatment; pidotimod was associated with fewer upper RTI recurrences compared with no treatment (1.43 vs. 3.82). A prospective cohort study with moderate risk of bias compared 532 palivizumab treated children with 233 untreated children and found that children treated with palivizumab had fewer respiratory syncytial virus-related hospitalization (23 untreated and 8 treated), but the same number of overall RTI-related hospitalizations (73 untreated and 74 treated) in the first 2 years of life.

CONCLUSIONS

The evidence base for the management of RTIs in people with Down's syndrome is incomplete; current studies included children only and carry a moderate to serious risk of bias. Methodologic rigorous studies are warranted to guide clinicians in how best to prevent and treat RTIs in children with Down's syndrome.

摘要

目的

系统评价唐氏综合征患者呼吸道感染(RTIs)预防和治疗干预措施的有效性。

方法

检索数据库,查找有关唐氏综合征儿童和成人呼吸道疾病的已发表和正在进行的研究。在这些数据库中检索对照试验、队列研究和前后对照研究。在试验注册库中检索正在进行的研究。最初,纳入所有研究类型以全面概述现有证据基础。然而,使用Cochrane偏倚风险工具排除了那些存在严重偏倚风险的研究。

结果

共识别出13575条记录,其中5项研究符合纳入标准,3项符合数据提取标准。一项偏倚风险为中度的随机对照试验比较了锌疗法与安慰剂。仅报告了50名(78%)出现极端症状儿童的结果数据;未发现锌疗法有任何益处。一项偏倚风险严重的非随机对照试验纳入了26名儿童,比较了匹多莫德(一种免疫刺激剂)与不治疗;与不治疗相比,匹多莫德与上呼吸道感染复发次数减少相关(1.43比3.82)。一项偏倚风险为中度的前瞻性队列研究比较了532名接受帕利珠单抗治疗的儿童与233名未治疗儿童,发现接受帕利珠单抗治疗的儿童呼吸道合胞病毒相关住院次数较少(23名未治疗儿童和8名治疗儿童),但在生命的前两年总体呼吸道感染相关住院次数相同(73名未治疗儿童和74名治疗儿童)。

结论

唐氏综合征患者呼吸道感染管理的证据基础不完整;目前的研究仅包括儿童,且存在中度至严重的偏倚风险。需要进行方法学严谨的研究,以指导临床医生如何最好地预防和治疗唐氏综合征儿童的呼吸道感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0bf/5130062/96142348626c/inf-35-1075-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验